PMID- 27470393
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20170207
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 82
DP  - 2016 Aug
TI  - IGF1R and c-met as therapeutic targets for colorectal cancer.
PG  - 528-36
LID - S0753-3322(16)30214-1 [pii]
LID - 10.1016/j.biopha.2016.05.034 [doi]
AB  - The type 1 IGF receptor (IGF1R) and mesenchymal-epithelial transition (MET) are 
      hetrodimeric and transmembrane receptor tyrosine kinases, which are frequently 
      overexpressed by several tumor types, including colorectal cancer (CRC). These 
      receptors bind to their specific ligands, insulin growth factors (IGFs) and 
      hepatocyte growth factor (HGF), respectively, and promote signaling cascades 
      which mediates many functions such as proliferation and protection against 
      apoptosis, cell scattering, tumor cell motility, invasion and metastasis. In 
      patients with metastatic colorectal cancer (mCRC), IGF1R and c-met expression 
      confer resistance to cetuximab (monoclonal antibodies against EGFR). Therefore, 
      the c-met and IGF1R are now an attractive novel target for anticancer therapy. In 
      this review, we will describe correlation between two receptors and their 
      activation effects in tumor cells, and finally introduce useful and available 
      strategies for their targeting.
CI  - Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.
FAU - Shali, Hajar
AU  - Shali H
AD  - Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical 
      Sciences, Tabriz, Iran; Student's Research Committee, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Ahmadi, Majid
AU  - Ahmadi M
AD  - Immunology research center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Kafil, Hossein Samadi
AU  - Kafil HS
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Dorosti, Abbasali
AU  - Dorosti A
AD  - Department of Anesthesiology, School of Medicine, Imam reza Hospital, Tabriz 
      University of Medical Sciences, Tabriz, Iran. Electronic address: 
      Dorostia@gmail.com.
FAU - Yousefi, Mehdi
AU  - Yousefi M
AD  - Immunology research center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran. Electronic address: Yousefime@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160606
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Animals
MH  - Colorectal Neoplasms/*metabolism/*therapy
MH  - Humans
MH  - Models, Biological
MH  - *Molecular Targeted Therapy
MH  - Proto-Oncogene Proteins c-met/*metabolism
MH  - Receptor, IGF Type 1/*metabolism
OTO - NOTNLM
OT  - Colorectal cancer
OT  - IGF1R
OT  - Receptor tyrosine kinase
OT  - c-Met
EDAT- 2016/07/30 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/07/30 06:00
PHST- 2016/02/22 00:00 [received]
PHST- 2016/05/01 00:00 [revised]
PHST- 2016/05/02 00:00 [accepted]
PHST- 2016/07/30 06:00 [entrez]
PHST- 2016/07/30 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - S0753-3322(16)30214-1 [pii]
AID - 10.1016/j.biopha.2016.05.034 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2016 Aug;82:528-36. doi: 10.1016/j.biopha.2016.05.034. Epub 
      2016 Jun 6.